Navigation Links
More U.S. Kids Prescribed Off-Label Antipsychotics: Study
Date:9/18/2012

TUESDAY, Sept. 18 (HealthDay News) -- Over the past decade, off-label use of antipsychotic drugs has increased among children enrolled in Medicaid, according to a new study representing 35 percent of children in the United States.

Off-label drug use is a term used to describe when drugs are prescribed using a dosage, type of dosage or for a purpose that hasn't yet been approved by the U.S. Food and Drug Administration.

In the study, researchers from the Children's Hospital of Philadelphia found a 62 percent jump in the number of publicly insured children between the ages of 3 and 18 taking antipsychotics. In 2007 alone, 65 percent of the 354,000 children on these drugs were taking them for uses that have not been approved by the FDA, the investigators pointed out.

"We knew that the number of children prescribed antipsychotics had grown steadily over the past two decades, particularly among children with public insurance," study author Meredith Matone, a researcher at PolicyLab, said in a hospital news release. "With this study, we wanted to learn more about why these drugs are being used so often, what diagnoses they're being used to treat, and how prescribing patterns changed over the course of the last decade."

The researchers pointed out that the spike in off-label antipsychotic use may be partly due to a 28 percent increase in the number of children diagnosed with a mental health disorder. Off-label use of these drugs is primarily associated with treatment for attention-deficit/hyperactivity disorder (ADHD) or conduct disorder. The researchers noted that in 2007, 50 percent of children taking antipsychotics were diagnosed with ADHD, and 14 percent of these had ADHD as their only diagnosis.

Children diagnosed with three or more mental health disorders were also among the largest group of kids taking antipsychotics. Children diagnosed with schizophrenia, bipolar disorder and autism were also most likely to be prescribed antipsychotics, according to the study published Sept. 10 in Health Services Research.

"The fact that we see an uptick in prescribing antipsychotics for many diagnoses tells us that antipsychotics are likely being used to treat specific behaviors, like aggression, that are shared among a variety of mental health diagnoses," Matone explained in the news release.

The increase in off-label use of antipsychotics, however, is a growing concern because these drugs have been linked to greater risk for serious side effects in children, including weight gain and diabetes, the researchers pointed out.

"If a child is prescribed an antipsychotic, it's important for doctors to inform parents and caregivers if the drug is being prescribed off-label, of potential side effects, and of counseling therapies that might be offered as an alternative to medication," study senior author, Dr. David Rubin, attending pediatrician, and co-director of the Children's Hospital of Philadelphia PolicyLab, said in the news release. "Given the significant proportion of off-label use of antipsychotics in children, it is reassuring that these drugs have been recognized as a priority for pediatric research by the [U.S.] National Institutes of Health."

The researchers concluded that more large-scale studies are needed to help formulate policies and guidelines for the use of antipsychotics among children.

More information

The U.S. Food and Drug Administration has more about off-label drug use.

-- Mary Elizabeth Dallas

SOURCE: Children's Hospital of Philadelphia, news release, Sept. 10, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New federal disclosure law may have little impact on drugs prescribed
2. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
3. Patients Often Kept in Dark About Off-Label Drug Use: Study
4. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
5. Reducing off-label use of antipsychotic medications may save money
6. Off-Label Drug Use Appears Common
7. Least Aggressive Breast Cancer Still Poses Long-Term Risk, Study Finds
8. Belly Fat Adds to Diabetes Risk in Obese Adults, Study Finds
9. BPA in Food Packaging Tied to Child Obesity: Study
10. Study finds least aggressive form of breast cancer still poses risk for death years later
11. New Study Debunks Virus Theory for Chronic Fatigue Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More U.S. Kids Prescribed Off-Label Antipsychotics: Study
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
(Date:3/28/2017)... GA (PRWEB) , ... March 28, 2017 , ... With ... to Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville ... location since 2016. The new office allows opportunity for transition of Patten Seed operations ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing immunogene ... Chief Operating Officer, is scheduled to present a corporate overview at ... Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 ... ... Future Leaders in Biotech Industry – Friday, April 7, 2017 at ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
Breaking Medicine Technology: